Gyrus beats dollar to grow in double digits in 2004
This article was originally published in Clinica
Despite the unfavourable dollar-sterling exchange rate, Reading, UK-based device company Gyrus reported 11% sales growth to £87m ($165m) in 2004. At constant exchange rates, revenues were up by 22%, it said. Profit before tax and goodwill amortisation was up 26% at £10.2m.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.